Core Viewpoint - Furuida (600223) is divesting non-core assets to focus on its main businesses in pharmaceuticals and cosmetics, with the recent sale of its 100% stake in Shandong Lushang Yintai Commercial Management Co., Ltd. for 88.4028 million yuan [1][3][4] Group 1: Asset Sale Details - The transaction involves the transfer of 100% equity of Lushang Yintai to Lushang Furuida Health Investment Co., Ltd., both controlled by Shandong Provincial Commercial Group Co., Ltd., constituting a related party transaction [1][3] - Lushang Yintai reported losses, with projected revenues of approximately 6.4036 million yuan and -6.235 million yuan in net profit for 2024, and 3.6607 million yuan and -8.768 million yuan for the first half of 2025 [3][4] - The valuation method used for the transaction was the asset-based approach, with a valuation date of December 31, 2024, resulting in a total equity valuation of 88.4028 million yuan [3][4] Group 2: Strategic Implications - The sale is part of Furuida's strategy to optimize resource allocation and focus on its core businesses, which include cosmetics and pharmaceuticals, aligning with its long-term development plans [4] - Furuida has been undergoing a transformation by divesting from real estate, with significant asset sales initiated in late 2022, leading to a substantial increase in net profit in 2023 [4] - Despite the divestment strategy, Furuida experienced a decline in revenue and net profit in 2024, with revenues of approximately 3.983 billion yuan and a net profit of about 244 million yuan, reflecting a year-on-year decrease of 13.02% and 19.73%, respectively [6]